Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

513
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
513
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K
Amyloid Fibrils03:03

Amyloid Fibrils

11.0K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of Tumor-Immune Cell Communications via Enantioselectively Targeting SLC G-Quadruplexes.

Journal of the American Chemical Society·2026
Same author

Neuron-targeting piezoelectric microneedles disrupt pro-tumorigenic neuron-immune crosstalk and restore anti-tumor immunity in melanoma.

Nature communications·2026
Same author

Modular Vaccine Robots for Spatiotemporal Programming of the CD4<sup>+</sup> T Cell-Myeloid Cell Axis.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Frustrated Lewis Pair-Induced Pre-Adsorbed Oxygen Coupled With Reactant Availability as a Design Strategy for High-Performance Single-Atom Nanozymes.

Angewandte Chemie (International ed. in English)·2026
Same author

An orally administrable hydrogen-bonded organic framework (HOF)-based nanoreactor to reprogram metabolism for senescence intervention.

National science review·2026
Same author

Nucleoside-ATTEC Conjugates for Targeting Inhibition of HIV Replication and Infection.

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: Nov 8, 2025

A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.2K

Current Strategies for Modulating Aβ Aggregation with Multifunctional Agents.

Zhi Du1,2, Meng Li1,2, Jinsong Ren1,3

  • 1Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, P. R. China.

Accounts of Chemical Research
|April 21, 2021
PubMed
Summary
This summary is machine-generated.

Researchers developed multifunctional agents and nanoparticles to combat Alzheimer's disease (AD) by targeting amyloid-beta (Aβ) aggregation and associated pathologies, offering new therapeutic strategies for neurodegenerative disorders.

More Related Videos

Intracerebroventricular Injection of Amyloid-&#946; Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

43.5K
Preparation of Oligomeric &#946;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.5K

Related Experiment Videos

Last Updated: Nov 8, 2025

A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.2K
Intracerebroventricular Injection of Amyloid-&#946; Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

43.5K
Preparation of Oligomeric &#946;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.5K

Area of Science:

  • Neuroscience and Pharmacology
  • Biochemistry and Molecular Biology
  • Materials Science and Nanotechnology

Background:

  • Alzheimer's disease (AD) is a leading cause of dementia, characterized by amyloid-beta (Aβ) aggregation and associated neurotoxicity.
  • Copper ions (Cu(II)) exacerbate Aβ aggregation and reactive oxygen species (ROS) production in the AD brain.
  • Current therapeutic strategies for AD face challenges in efficacy and targeting specific pathological pathways.

Purpose of the Study:

  • To develop Aβ-targeted multifunctional molecules and nanoparticles for Alzheimer's disease therapy.
  • To explore synergistic therapeutic effects by combining multiple inhibition strategies and targeting diverse pathological factors.
  • To investigate the potential of multifunctional platforms for integrated diagnostics and therapeutics, including BBB translocation and stimuli-responsive drug delivery.

Main Methods:

  • Design and synthesis of multifunctional agents and nanoparticles targeting Aβ aggregation.
  • Evaluation of Aβ aggregation inhibition, modulation of oxidative stress, and neuroprotection.
  • Integration of diagnostic modalities (e.g., in situ imaging) and therapeutic delivery systems with BBB crossing capabilities.

Main Results:

  • Multifunctional agents demonstrated efficient Aβ aggregation blockage through multiple Aβ-specific inhibition strategies.
  • These agents modulated additional AD pathological factors, including oxidative stress and copper accumulation.
  • Integrated platforms showed potential for improved drug delivery, reduced side effects, and enhanced therapeutic evaluation.

Conclusions:

  • Multifunctional agents and nanoparticles offer a promising therapeutic avenue for Alzheimer's disease by addressing multiple pathological hallmarks.
  • The developed strategies provide a framework for creating advanced therapeutic agents for neurodegenerative diseases.
  • Further research into Aβ aggregate interactions with DNA may reveal novel therapeutic targets.